NCT02473939

An Evaluation of VR942 in Healthy Volunteers and Patients With Mild Asthma

A Randomised, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of VR942 in Healthy Subjects and Repeated Doses in Mild Asthmatics

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 85 (actual)
• Sponsor: Vectura Limited · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to Evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of VR942 in healthy subjects (part 1) and repeated doses in mild asthmatics (part 2).

Conditions

• Asthma

Interventions

Type	Name	Description
DRUG	VR942 delivered via a Vectura Dry Powder Inhaler
DRUG	Placebo delivered via a Vectura Dry Powder Inhaler

Timeline

• Start date: 2015-06-01
• Primary completion: 2016-04-01
• First posted: 2015-06-17
• Last updated: 2016-12-21

Locations

1 site across 1 country: United Kingdom